What a CEO makes can be staggering from the seat of a rank-and-file employee, whose pay is typically in the five-to-six digit ...

Policy uncertainties are impacting biopharma dealmaking from continent to continent, with companies being asked to walk a ...

As Q1 2025 earnings season continues, tariffs remain top of mind for pharma CEOs and investors. Meanwhile, the American Association for Cancer Research’s annual event kicks off this year’s oncology ...

Nevertheless, Albert Bourla has been lobbying the U.S. government—as high as President Donald Trump himself—to skip the ...

Following the recent discontinuations of assets in Alzheimer’s and migraine, AstraZeneca is stepping away from neuro ...

The company’s $3 billion in earnings for the first quarter missed on both top and bottom line, according to BMO Capital ...

Vas Narasimhan said on Tuesday that if the U.S. adopts international drug pricing, all companies would have to “relook at ...

While Vaxart can proceed with its study, fellow COVID-19 vaccine developers GeoVax and Novavax continue to be hamstrung by ...

Major pharmaceutical companies are committing billions to US manufacturing in an effort to avoid steep tariffs threatened by ...

The condition, recessive dystrophic epidermolysis bullosa, causes chronic wounds and has an 84% mortality rate by age 40.

Despite executing "perfectly," Octagon confronted a “scientific no-go,” CEO Isaac Stoner said in his LinkedIn post announcing ...

Pfizer’s R&D organization has been in flux for almost two years now, since the $43 billion acquisition of ADC specialist ...